Comparative Pharmacology
Head-to-head clinical analysis: JALYN versus PROSCAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JALYN versus PROSCAR.
JALYN vs PROSCAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.
Finasteride inhibits 5α-reductase type II, preventing conversion of testosterone to dihydrotestosterone (DHT) in the prostate, reducing prostate volume and improving urinary symptoms.
1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.
5 mg orally once daily.
None Documented
None Documented
Dutasteride: 5 weeks (t½ ∼3-5 weeks) due to high tissue binding and slow elimination; Tamsulosin: 9-13 hours (t½ ∼9-13 h) in healthy subjects, prolonged in elderly (∼14-15 h).
Terminal elimination half-life is 6-8 hours (range 4-12 hours) in young adults; prolonged to 8-10 hours in elderly (≥70 years), but no dose adjustment required. Steady-state reached after 2 weeks dosing.
Dutasteride: 40% renal, 60% fecal as metabolites; Tamsulosin: 76% renal (9% unchanged), 24% fecal as metabolites.
Primarily hepatic metabolism (CYP3A4), metabolites excreted renally (39%) and fecally (57%) as unchanged drug and metabolites.
Category C
Category C
5-Alpha Reductase Inhibitor/Alpha-1 Blocker Combination
5-Alpha Reductase Inhibitor